Results 141 to 150 of about 2,379 (179)

Delayed Bullous Drug Eruption Induced by Elexacaftor/Tezacaftor/Ivacaftor

Pediatric Dermatology
ABSTRACT Elexacaftor/tezacaftor/ivacaftor is a novel “triple therapy” drug which has been shown in clinical trials to reduce morbidity and mortality in cystic fibrosis patients. Few reports of serious cutaneous adverse reactions to elexacaftor/tezacaftor/ivacaftor leading to drug discontinuation have been previously documented, all ...
Tatiana Ninkov, Megan Yap, Nima Mesbah Ardakani, Peter Le Souef, Kurt Gebauer, Rachael Foster   +5 more
openaire   +2 more sources

Elexacaftor/tezacaftor/ivacaftor outpatient desensitization

Annals of Allergy, Asthma & Immunology, 2022
Ramya Balijepally, Denise Kwong, Linda Zhu, Juanita Valdes Camacho, Anne Liu   +4 more
openaire   +2 more sources

Effects of Elexacaftor/Tezacaftor/Ivacaftor on the Sinonasal Airspace in Cystic Fibrosis

The Laryngoscope
ABSTRACT Objectives People with Cystic Fibrosis ( CF ) experience significant sinonasal airway opacification, leading to chronic airway‐related conditions. The triple combination therapy Elexacaftor/Tezacaftor/Ivacaftor (
Michelle H. Kim, Nathan A. Luzum, Adam J. Kimple, Anna C. Zemke, Dennis Frank‐Ito   +4 more
openaire   +2 more sources

Patient perspectives on elexacaftor/tezacaftor/ivacaftor after lung transplant

Journal of Cystic Fibrosis
Cystic fibrosis transmembrane conductance regulator (CFTR) modulators, including elexacaftor/tezacaftor/ivacaftor (ETI), significantly improve outcomes and quality of life for people with cystic fibrosis (CF). However, little is known about how lung transplant recipients (LTRs) perceive the use of ETI.
Dave Young, Lauren E. Bartlett, Jennifer Guimbellot, Tijana Milinic, Nora Burdis, Eliana R. Gill, Erika D. Lease, Christopher H. Goss, Siddhartha G. Kapnadak, Kathleen J. Ramos   +9 more
openaire   +2 more sources

Efficacy of Elexacaftor–Tezacaftor–Ivacaftor on chronic rhinosinusitis in cystic fibrosis

American Journal of Otolaryngology
Our work aims to add evidence on the effectiveness of Elexacaftor-Tezacaftor-Ivacaftor on chronic rhinosinusitis in cystic fibrosis.We conducted an observational retrospective cohort study at the Cystic Fibrosis Center of a tertiary care hospital to investigate the effect of Elexacaftor-Tezacaftor-Ivacaftor on chronic rhinosinusitis in cystic fibrosis ...
Di Gioia, Stefano, Lucca, Francesca, Venditto, Laura, Sandri, Giulio, Tommasi, Nicola, Cipolli, Marco, Molteni, Gabriele   +6 more
openaire   +3 more sources

Heterogeneity in response to Elexacaftor/Tezacaftor/Ivacaftor in people with cystic fibrosis

Journal of Cystic Fibrosis
Highly effective modulators of the CFTR channel have been demonstrated to dramatically impact disease progression and outcome. However, real-world data indicates that the magnitude of the clinical benefit is not equal among all patients receiving the treatment.
Gianfranco Alicandro, Andrea Gramegna, Federica Bellino, Sathya Calogero Sciarrabba, Chiara Lanfranchi, Martina Contarini, Mariangela Retucci, Valeria Daccò, Francesco Blasi   +8 more
openaire   +2 more sources

Effects of elexacaftor–tezacaftor–ivacaftor discontinuation in cystic fibrosis

Respiratory Medicine and Research, 2022
Georgia Mitropoulou, Zisis Balmpouzis, Jérôme Plojoux, Jennifer Dotta-Celio, Alain Sauty, Angela Koutsokera   +5 more
openaire   +2 more sources

Elexacaftor–tezacaftor–ivacaftor use after solid organ transplant

Current Opinion in Pulmonary Medicine
Purpose of review In 2019, the United States Food and Drug Administration approved a breakthrough therapeutic for cystic fibrosis, elexacaftor–tezacaftor–ivacaftor (ETI), because of its profound effect on lung function in large phase III clinical trials.
Siddhartha G, Kapnadak, Kathleen J, Ramos   +1 more
openaire   +2 more sources

P151 Pregnancies with elexacaftor/tezacaftor/ivacaftor in Argentina

Journal of Cystic Fibrosis, 2023
E. Baran, L. Osken, N. Bergas Gimbernat
openaire   +1 more source

Elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and rare mutations

Pediatric Pulmonology
Abstract Introduction The triple combination of elexacaftor/tezacaftor/ivacaftor (ETI) has dramatically improved the outcome of people with Cystic Fibrosis (pwCF) with at least one F508del mutation.
Fainardi, Valentina, Cresta, Federico, Sorio, Claudio, Melotti, Paola, Pesce, Emanuela, Deolmi, Michela, Longo, Francesco, Karina, Kleinfelder, Esposito, Susanna, Pisi, Giovanna   +9 more
openaire   +4 more sources